BA PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BA PHARMA is 1.6% (moderate). The 2025 annual accounts show equity of €146,387 and a net result of €689. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 18% of 12,578 sector peers (NACE 47, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
28-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
20-06
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
31-12
Financial
Back to profitnet €1,179
Net result €1,179 after one loss-making year.
09-07
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
31-12
Financial
Weakest financial yearnet -€1,000
Net result drops to -€1,000, the lowest in the series; recovery starts the following year.
08-06
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
13-06
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Highest result from 2019 to 2025net €48,481 ▲26.2%
Operating result €89,202, net result €48,481, both a record.
31-12
Financial
Equity above €100,000equity €111,810 ▲76.6%
A profit in every financial year since 2019 builds equity to €111,810.
31-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 31 days late
2020
29-09
NBB filing
Annual accounts filed
financial year 2019 · micro format · 60 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 5 deeds read
About the unread acts
We know of 5 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.